​

​

• Johnson & Johnson  

          A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus            Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

​Study Details | NCT07499232 | A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | ClinicalTrials.gov

​

​

​

​

​

​

​

​​